News Sentiment

PRME sentiment intelligence

Prime Medicine, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 75 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 3.78 Week of 10 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 68

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend inactive

-2.3% over one week, +36.2% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Prime Medicine (PRME) Reaches Positive Resolution to Arbitration with Beam Therapeutics

Market Reaction

Balanced read

67/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction -2.3% Price reacting lower
Trend fit Trend inactive 36.2% over four weeks
Fair value -24.4% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 26
Neutral 42
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 68
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Market source 7
Investing.com 6
TradingView 5
Moomoo 5
Stock Titan 4
MarketBeat 3
Insider Monkey 2
timothysykes.com 2

Event Lens

What the news is about

Classified themes
Market update 38
Earnings 21
Analyst action 7
Regulatory and legal 6
Balance sheet 2
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 75
Insider Monkey Direct company coverage

10 Overlooked Penny Stocks to Buy Right Now

This article highlights Prime Medicine, Inc. (NASDAQ: PRME) as an overlooked penny stock with significant upside potential. The company recently received regulatory clearances for its gene-editing therapies, including acceptance of a clinical trial application for PM577a in New Z

Tone
Positive 71/100
Event
Regulatory and legal
Published
05 Jul 2026 00:10
Source
Insider Monkey
Finviz Direct company coverage

PRME - Prime Medicine Inc Options

This article provides a detailed financial overview of Prime Medicine Inc (PRME), including its last close price of $3.87, key valuation metrics like market cap and enterprise value, and various financial ratios. It also highlights performance indicators, analyst recommendations,

Tone
Neutral 50/100
Event
Analyst action
Published
03 Jul 2026 05:40
Source
Finviz
TradingView Direct company coverage

Enterprise value to revenue forward of Prime Medicine, Inc. – NASDAQ:PRME

This article provides a brief mention of Prime Medicine, Inc. (NASDAQ:PRME) and its enterprise value to revenue forward metric. The content appears to be a stub or a section within a larger financial data platform, indicating the availability of financial information for the comp

Tone
Neutral 50/100
Event
Earnings
Published
30 Jun 2026 18:43
Source
TradingView
TradingView Direct company coverage

Price to book forward of Prime Medicine, Inc. – NASDAQ:PRME

This article briefly highlights the "Price to book forward" metric for Prime Medicine, Inc., traded under the NASDAQ:PRME symbol. It appears to be a financial data point from a larger platform, likely TradingView, indicating specific financial information for the company. The con

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 04:01
Source
TradingView
Investing.com Direct company coverage

H.C. Wainwright upgrades Prime Medicine stock rating to buy

H.C. Wainwright has upgraded Prime Medicine (NASDAQ:PRME) from Neutral to Buy, setting an $8.00 price target after New Zealand approved the Clinical Trial Application for PM577a, an investigational therapy for Wilson’s Disease. This clearance marks the first clinical authorizatio

Tone
Positive 74/100
Event
Regulatory and legal
Published
29 Jun 2026 11:41
Source
Investing.com
Moomoo Direct company coverage

Prime Medicine Says PM359 Granted US FDA Regenerative Medicine Advanced Therapy Designation

Prime Medicine announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to PM359. PM359 is an investigational Prime Editor designed to correct the genetic cause of chronic granulomatous disease (CGD). The company previously received Orphan Drug

Tone
Positive 71/100
Event
Regulatory and legal
Published
22 Jun 2026 12:40
Source
Moomoo
Stock Titan Direct company coverage

Prime Medicine’s CGD therapy gets FDA RMAT, speeding review

Prime Medicine (PRME) has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA for its investigational therapy PM359, aimed at treating p47phox-deficient chronic granulomatous disease (CGD). This designation, supported by positive Phase 1/2 clinical d

Tone
Positive 85/100
Event
Regulatory and legal
Published
22 Jun 2026 11:59
Source
Stock Titan
GlobeNewswire Direct company coverage

Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

Prime Medicine, Inc. announced that the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to PM359 for the treatment of p47 phox -deficient chronic granulomatous disease (CGD). This designation is based on promising Phase 1/2 clinical data, including

Tone
Positive 71/100
Event
Market update
Published
22 Jun 2026 11:59
Source
GlobeNewswire
The Globe and Mail Direct company coverage

Analysts Are Bullish on These Healthcare Stocks: Prime Medicine, Inc. (PRME), Ocular Therapeutix (OCUL)

LifeSci Capital analyst Cory Jubinville maintained a Buy rating on Prime Medicine, Inc. (PRME) with a $6.00 price target. Needham analyst Serge Belanger also maintained a Buy rating on Ocular Therapeutix (OCUL) with an $18.00 price target, aligning with a Strong Buy consensus for

Tone
Neutral 50/100
Event
Analyst action
Published
20 Jun 2026 00:09
Source
The Globe and Mail